# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 14.6 | 103.0 | (57.6-169.9) |  | Male | 12 | 9.9 | 121.3 | (62.6-211.9) |
| Female | 7 | 5.3 | 131.2 | (52.6-270.3) |  | Female | 9 | 8.3 | 108.9 | (49.7-206.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.1 | nc | (nc-nc) |  | Male | 6 | 3.1 | 193.4 | (70.6-420.9) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 4 | 8.9 | nc | (nc-nc) |
| Female | 62 | 63.6 | 97.4 | (74.7-124.9) |  | Female | 5 | 7.7 | 64.5 | (20.8-150.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.5 | 79.5 | (29.0-173.0) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 16.4 | 116.0 | (69.8-181.2) |  |  |  |  |  |  |
| Female | 24 | 16.2 | 148.5 | (95.1-221.0) |  | Female | 7 | 5.6 | 124.4 | (49.8-256.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.1 | 120.9 | (39.0-282.2) |  | Male | 8 | 5.3 | 151.1 | (65.0-297.7) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 5.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 55 | 54.7 | 100.6 | (75.8-130.9) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 8.9 | 158.1 | (86.4-265.3) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 8 | 4.9 | 161.7 | (69.6-318.7) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 6 | 0.7 | 812.9 | (296.8-1769.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 6.1 | nc | (nc-nc) |  | Male | 5 | 4.2 | 117.9 | (38.0-275.0) |
| Female | 8 | 4.7 | 170.4 | (73.4-335.9) |  | Female | 17 | 12.6 | 134.4 | (78.3-215.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.5 | 91.3 | (29.4-213.0) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 20 | 14.8 | 135.3 | (82.6-208.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 26.6 | 154.0 | (110.5-209.0) |  | Male | 227 | 204.2 | 111.2 | (97.2-126.6) |
| Female | 36 | 28.2 | 127.7 | (89.4-176.8) |  | Female | 250 | 211.4 | 118.3 | (104.1-133.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

10

# Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 20.8 | 81.8 | (47.6-131.0) |  | Male | 14 | 14.3 | 97.9 | (53.5-164.2) |
| Female | 7 | 7.2 | 97.7 | (39.1-201.3) |  | Female | 18 | 11.3 | 159.9 | (94.7-252.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.6 | 152.8 | (61.2-314.9) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 5 | 3.3 | 149.4 | (48.1-348.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 17 | 12.9 | 131.7 | (76.7-210.9) |
| Female | 96 | 91.5 | 104.9 | (85.0-128.1) |  | Female | 11 | 10.6 | 103.8 | (51.8-185.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 11.1 | 108.1 | (55.8-188.9) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 24.3 | 65.9 | (37.6-107.0) |  |  |  |  |  |  |
| Female | 17 | 22.7 | 74.8 | (43.5-119.7) |  | Female | 15 | 7.9 | 189.9 | (106.2-313.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.9 | 102.3 | (37.3-222.6) |  | Male | 7 | 7.6 | 92.2 | (36.9-190.0) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 6 | 7.2 | 83.6 | (30.5-182.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 73 | 76.0 | 96.1 | (75.3-120.8) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 12.8 | 62.5 | (26.9-123.2) |  | Male | 1 | 5.1 | nc | (nc-nc) |
| Female | 7 | 6.9 | 101.7 | (40.7-209.5) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.9 | 78.7 | (31.5-162.3) |  | Male | 7 | 6.2 | 113.1 | (45.3-233.0) |
| Female | 12 | 6.1 | 195.6 | (100.9-341.7) |  | Female | 15 | 17.5 | 85.5 | (47.8-141.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 8.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 19 | 20.4 | 92.9 | (55.9-145.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 37.8 | 52.9 | (32.3-81.8) |  | Male | 242 | 292.2 | 82.8 | (72.7-93.9) |
| Female | 24 | 38.6 | 62.2 | (39.8-92.5) |  | Female | 292 | 293.9 | 99.3 | (88.3-111.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

11

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 12.6 | 150.4 | (90.5-234.8) |  | Male | 8 | 7.9 | 100.9 | (43.4-198.8) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 6 | 6.1 | 98.8 | (36.1-215.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 7.1 | 140.2 | (67.1-257.9) |
| Female | 44 | 48.6 | 90.6 | (65.8-121.6) |  | Female | 7 | 6.1 | 115.6 | (46.3-238.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 5.6 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 13.4 | 112.1 | (62.7-184.9) |  |  |  |  |  |  |
| Female | 12 | 12.9 | 92.7 | (47.8-161.9) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 7 | 4.4 | 159.2 | (63.8-328.1) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 51 | 39.8 | 128.1 | (95.4-168.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 6.6 | 136.7 | (62.4-259.6) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.0 | 100.0 | (32.2-233.4) |  | Male | 0 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.4 | 176.5 | (64.4-384.1) |  | Female | 9 | 8.5 | 105.3 | (48.1-199.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 9 | 11.1 | 80.8 | (36.9-153.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 21.9 | 132.4 | (88.6-190.1) |  | Male | 182 | 160.3 | 113.5 | (97.6-131.3) |
| Female | 22 | 23.8 | 92.3 | (57.8-139.8) |  | Female | 151 | 163.2 | 92.5 | (78.3-108.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

12

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.6 | 83.1 | (35.8-163.8) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 6 | 3.8 | 160.0 | (58.4-348.2) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.5 | 91.0 | (29.3-212.3) |
| Female | 35 | 39.5 | 88.6 | (61.7-123.3) |  | Female | 8 | 5.1 | 157.2 | (67.7-309.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 10.5 | 113.9 | (58.8-199.0) |  |  |  |  |  |  |
| Female | 14 | 11.4 | 122.8 | (67.1-206.0) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.7 | 133.7 | (43.1-311.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 38 | 33.2 | 114.3 | (80.9-157.0) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 7 | 7.0 | 100.6 | (40.3-207.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 8.7 | 69.3 | (25.3-150.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 17.2 | 104.7 | (62.0-165.5) |  | Male | 125 | 126.8 | 98.6 | (82.1-117.5) |
| Female | 32 | 19.7 | 162.3 | (111.0-229.1) |  | Female | 145 | 135.6 | 107.0 | (90.3-125.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

13

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 32.4 | 111.2 | (77.9-154.0) |  | Male | 20 | 20.7 | 96.7 | (59.0-149.3) |
| Female | 11 | 13.6 | 81.1 | (40.4-145.2) |  | Female | 16 | 17.9 | 89.5 | (51.1-145.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.1 | 81.8 | (26.4-191.0) |  | Male | 9 | 6.5 | 137.7 | (62.8-261.3) |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 5 | 6.0 | 83.1 | (26.8-193.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 23 | 18.5 | 124.3 | (78.8-186.5) |
| Female | 153 | 139.6 | 109.6 | (92.9-128.4) |  | Female | 19 | 18.3 | 103.7 | (62.4-162.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 15.0 | 153.5 | (97.2-230.3) |
| Female | 9 | 4.5 | 201.1 | (91.8-381.9) |  | Female | 13 | 7.6 | 170.1 | (90.5-290.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 34.8 | 123.4 | (89.3-166.2) |  |  |  |  |  |  |
| Female | 35 | 41.1 | 85.2 | (59.3-118.5) |  | Female | 12 | 12.6 | 95.1 | (49.1-166.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 8.6 | 58.2 | (18.8-135.9) |  | Male | 11 | 11.4 | 96.6 | (48.1-172.8) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 17 | 13.8 | 123.5 | (71.9-197.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 92 | 108.6 | 84.7 | (68.3-103.9) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 17.6 | 130.7 | (82.8-196.2) |  | Male | 11 | 7.6 | 144.8 | (72.2-259.2) |
| Female | 7 | 11.2 | 62.5 | (25.0-128.7) |  | Female | 5 | 5.3 | 93.7 | (30.2-218.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.0 | 140.0 | (56.1-288.5) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 12.9 | 101.0 | (53.7-172.7) |  | Male | 7 | 7.9 | 88.8 | (35.6-183.0) |
| Female | 9 | 10.6 | 84.6 | (38.6-160.6) |  | Female | 19 | 24.0 | 79.2 | (47.6-123.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 11.2 | 80.0 | (36.5-151.9) |  |  |  |  |  |  |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 28 | 31.7 | 88.3 | (58.6-127.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 57.6 | 142.3 | (113.2-176.6) |  | Male | 448 | 423.2 | 105.9 | (96.3-116.1) |
| Female | 84 | 68.3 | 122.9 | (98.1-152.2) |  | Female | 490 | 482.5 | 101.6 | (92.8-111.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

14

# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 2 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 4 | 14.1 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 9 | 10.0 | 90.0 | (41.1-170.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

15

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 13.6 | 169.7 | (107.5-254.7) |  | Male | 8 | 9.9 | 80.6 | (34.7-158.8) |
| Female | 10 | 6.0 | 167.8 | (80.3-308.6) |  | Female | 6 | 9.0 | 66.6 | (24.3-145.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 6 | 2.8 | 218.0 | (79.6-474.6) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 11 | 8.9 | 124.2 | (61.9-222.2) |
| Female | 77 | 70.3 | 109.5 | (86.4-136.8) |  | Female | 11 | 8.6 | 128.1 | (63.9-229.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 7.9 | 151.2 | (78.1-264.2) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.9 | (44.1-319.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 16.0 | 149.6 | (95.8-222.6) |  |  |  |  |  |  |
| Female | 25 | 18.6 | 134.2 | (86.8-198.1) |  | Female | 5 | 6.2 | 81.0 | (26.1-189.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 9 | 5.1 | 175.1 | (79.9-332.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.4 | (46.6-239.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 61 | 54.8 | 111.4 | (85.2-143.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 9.1 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.0 | 133.2 | (57.4-262.5) |  | Male | 5 | 4.6 | 108.7 | (35.0-253.6) |
| Female | 7 | 5.0 | 140.1 | (56.1-288.7) |  | Female | 16 | 13.7 | 116.9 | (66.8-189.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 11 | 15.7 | 69.9 | (34.8-125.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 25.7 | 120.7 | (82.0-171.4) |  | Male | 237 | 202.7 | 116.9 | (102.5-132.8) |
| Female | 40 | 31.3 | 127.9 | (91.4-174.2) |  | Female | 252 | 233.2 | 108.1 | (95.1-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

16

# Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 18.6 | 86.0 | (49.1-139.7) |  | Male | 11 | 12.4 | 88.4 | (44.1-158.2) |
| Female | 3 | 7.1 | nc | (nc-nc) |  | Female | 13 | 12.0 | 108.7 | (57.8-185.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  | Male | 5 | 3.7 | 136.2 | (43.9-317.9) |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 6 | 12.0 | 49.9 | (18.2-108.6) |
| Female | 72 | 75.9 | 94.8 | (74.2-119.4) |  | Female | 15 | 10.5 | 142.3 | (79.6-234.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.7 | 103.9 | (47.4-197.2) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 19.7 | 81.3 | (46.4-132.0) |  |  |  |  |  |  |
| Female | 25 | 21.5 | 116.2 | (75.2-171.5) |  | Female | 12 | 7.6 | 158.1 | (81.6-276.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 9 | 6.5 | 138.9 | (63.4-263.8) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 7 | 7.0 | 99.5 | (39.9-205.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  | Male | 47 | 62.6 | 75.1 | (55.2-99.9) |
| Female | 0 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 10.0 | 49.9 | (16.1-116.4) |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 5 | 6.2 | 80.2 | (25.9-187.2) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 6.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 9.2 | 109.2 | (52.3-200.8) |  | Male | 6 | 5.7 | 105.7 | (38.6-230.0) |
| Female | 5 | 7.0 | 71.8 | (23.1-167.6) |  | Female | 4 | 19.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 12 | 17.6 | 68.1 | (35.1-118.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 33.3 | 45.0 | (25.2-74.2) |  | Male | 179 | 258.3 | 69.3 | (59.5-80.2) |
| Female | 20 | 37.0 | 54.1 | (33.0-83.5) |  | Female | 225 | 277.8 | 81.0 | (70.7-92.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

17

# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 34.6 | 72.3 | (46.8-106.8) |  | Male | 23 | 22.5 | 102.4 | (64.9-153.7) |
| Female | 9 | 13.3 | 67.7 | (30.9-128.6) |  | Female | 27 | 19.0 | 141.9 | (93.5-206.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.8 | 102.5 | (41.1-211.3) |  | Male | 9 | 7.2 | 125.3 | (57.2-237.8) |
| Female | 5 | 6.0 | 83.2 | (26.8-194.1) |  | Female | 9 | 6.0 | 148.8 | (67.9-282.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 26 | 20.2 | 128.8 | (84.1-188.7) |
| Female | 159 | 153.8 | 103.4 | (87.9-120.8) |  | Female | 21 | 18.8 | 111.8 | (69.2-171.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 16.8 | 101.3 | (59.0-162.1) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 4 | 8.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 38.1 | 78.8 | (53.1-112.5) |  |  |  |  |  |  |
| Female | 29 | 40.7 | 71.3 | (47.7-102.4) |  | Female | 14 | 13.5 | 103.9 | (56.7-174.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 9.5 | 84.6 | (36.4-166.7) |  | Male | 11 | 12.3 | 89.3 | (44.5-159.7) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 11 | 13.4 | 82.3 | (41.0-147.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 113 | 122.1 | 92.6 | (76.3-111.3) |
| Female | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 19.6 | 91.6 | (54.3-144.8) |  | Male | 5 | 8.2 | 61.0 | (19.7-142.4) |
| Female | 11 | 12.0 | 91.8 | (45.8-164.3) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 7 | 4.2 | 166.9 | (66.9-343.9) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 14.0 | 143.3 | (87.5-221.3) |  | Male | 15 | 8.9 | 168.8 | (94.4-278.5) |
| Female | 10 | 10.9 | 91.5 | (43.8-168.3) |  | Female | 37 | 27.6 | 134.2 | (94.5-185.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 12.5 | 64.1 | (27.6-126.3) |  |  |  |  |  |  |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 24 | 34.8 | 69.0 | (44.2-102.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 62.4 | 60.9 | (43.1-83.6) |  | Male | 421 | 464.5 | 90.6 | (82.2-99.7) |
| Female | 38 | 70.6 | 53.8 | (38.1-73.8) |  | Female | 454 | 509.6 | 89.1 | (81.1-97.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

18

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.5 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

19

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 45.9 | 93.7 | (67.8-126.2) |  | Male | 25 | 29.8 | 83.9 | (54.3-123.8) |
| Female | 16 | 17.8 | 89.9 | (51.3-145.9) |  | Female | 26 | 25.4 | 102.3 | (66.8-149.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 9.0 | 89.1 | (38.4-175.7) |  | Male | 10 | 9.3 | 107.8 | (51.6-198.2) |
| Female | 9 | 7.7 | 117.1 | (53.4-222.3) |  | Female | 4 | 8.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 19 | 26.7 | 71.2 | (42.8-111.2) |
| Female | 212 | 195.0 | 108.7 | (94.6-124.4) |  | Female | 33 | 24.9 | 132.4 | (91.1-185.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 21.3 | 89.4 | (53.8-139.6) |
| Female | 2 | 6.9 | nc | (nc-nc) |  | Female | 15 | 10.5 | 142.9 | (79.9-235.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 50.2 | 85.7 | (62.0-115.4) |  |  |  |  |  |  |
| Female | 45 | 54.8 | 82.1 | (59.9-109.9) |  | Female | 16 | 17.4 | 91.8 | (52.4-149.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 12.0 | 108.5 | (57.7-185.5) |  | Male | 18 | 16.1 | 111.8 | (66.2-176.8) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 21 | 18.2 | 115.5 | (71.5-176.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 149 | 149.8 | 99.5 | (84.1-116.8) |
| Female | 5 | 2.8 | 175.9 | (56.7-410.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 25.3 | 114.7 | (76.8-164.8) |  | Male | 9 | 10.9 | 82.9 | (37.8-157.5) |
| Female | 13 | 15.3 | 84.8 | (45.1-145.1) |  | Female | 5 | 7.1 | 70.4 | (22.7-164.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 7.0 | nc | (nc-nc) |  | Male | 8 | 6.6 | 120.8 | (52.0-238.0) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 18.6 | 85.9 | (49.1-139.5) |  | Male | 12 | 11.8 | 101.6 | (52.5-177.6) |
| Female | 11 | 14.5 | 75.6 | (37.7-135.3) |  | Female | 35 | 36.9 | 94.7 | (66.0-131.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 15.7 | 108.0 | (62.9-173.0) |  |  |  |  |  |  |
| Female | 2 | 5.6 | nc | (nc-nc) |  | Female | 49 | 43.8 | 112.0 | (82.8-148.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 69 | 80.8 | 85.4 | (66.4-108.1) |  | Male | 554 | 599.8 | 92.4 | (84.8-100.4) |
| Female | 87 | 90.7 | 95.9 | (76.8-118.3) |  | Female | 670 | 663.6 | 101.0 | (93.5-108.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

20

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.4 | 110.6 | (40.4-240.6) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 18 | 26.4 | 68.1 | (40.3-107.6) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 6.1 | 81.6 | (26.3-190.5) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 21 | 23.4 | 89.6 | (55.5-137.0) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.4 | 209.5 | (67.5-489.0) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 6.0 | 83.3 | (26.9-194.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 10.4 | 57.4 | (21.0-125.0) |  | Male | 69 | 82.7 | 83.5 | (64.9-105.6) |
| Female | 6 | 11.3 | 53.1 | (19.4-115.6) |  | Female | 63 | 83.6 | 75.4 | (57.9-96.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

21

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 5 | 2.2 | 229.9 | (74.1-536.4) |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 12 | 14.2 | 84.5 | (43.6-147.6) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 4 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 11 | 11.8 | 93.5 | (46.6-167.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.8 | nc | (nc-nc) |  | Male | 45 | 44.7 | 100.6 | (73.4-134.6) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 45 | 46.1 | 97.6 | (71.2-130.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

22

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.0 | nc | (nc-nc) |
| Female | 9 | 9.8 | 91.9 | (41.9-174.5) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.2 | (23.3-168.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 24 | 23.5 | 101.9 | (65.3-151.7) |
| Female | 1 | 4.6 | nc | (nc-nc) |  | Female | 24 | 32.4 | 74.1 | (47.4-110.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

23

# Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 15.7 | 95.4 | (53.3-157.3) |  | Male | 8 | 10.8 | 74.1 | (31.9-146.1) |
| Female | 2 | 6.5 | nc | (nc-nc) |  | Female | 4 | 9.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 5 | 3.3 | 149.7 | (48.3-349.4) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 9.8 | 81.9 | (35.3-161.4) |
| Female | 67 | 77.6 | 86.4 | (66.9-109.7) |  | Female | 7 | 9.3 | 75.1 | (30.1-154.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 8.5 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.0 | 124.0 | (39.9-289.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 18.5 | 64.9 | (33.5-113.4) |  |  |  |  |  |  |
| Female | 22 | 19.9 | 110.6 | (69.3-167.5) |  | Female | 9 | 6.8 | 131.9 | (60.2-250.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 4.4 | 203.7 | (93.0-386.7) |  | Male | 5 | 5.8 | 86.5 | (27.9-201.8) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 6.5 | 76.9 | (24.8-179.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 40 | 57.0 | 70.2 | (50.1-95.5) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.6 | 83.2 | (35.8-163.9) |  | Male | 6 | 3.9 | 154.7 | (56.5-336.6) |
| Female | 2 | 6.0 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 6.7 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 8 | 5.4 | 148.4 | (63.9-292.3) |  | Female | 21 | 14.3 | 146.7 | (90.8-224.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.1 | 82.4 | (26.5-192.2) |  |  |  |  |  |  |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 17 | 18.1 | 94.0 | (54.7-150.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 28.2 | 92.1 | (60.2-135.0) |  | Male | 178 | 220.0 | 80.9 | (69.5-93.7) |
| Female | 39 | 34.1 | 114.3 | (81.2-156.2) |  | Female | 234 | 254.6 | 91.9 | (80.5-104.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

24

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 14.1 | 127.3 | (75.4-201.2) |  | Male | 4 | 9.2 | nc | (nc-nc) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 5 | 8.0 | 62.1 | (20.0-145.0) |
| Female | 36 | 47.8 | 75.4 | (52.8-104.4) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.6 | 121.6 | (52.4-239.7) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.9 | 120.6 | (71.5-190.7) |  |  |  |  |  |  |
| Female | 15 | 13.2 | 113.3 | (63.4-186.9) |  | Female | 5 | 4.3 | 116.4 | (37.5-271.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.8 | 131.2 | (42.3-306.3) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 29 | 48.6 | 59.7 | (39.9-85.7) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.7 | 103.7 | (44.6-204.3) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 5 | 3.5 | 141.7 | (45.7-330.6) |  | Female | 12 | 8.7 | 138.4 | (71.4-241.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 23 | 11.1 | 207.4 | (131.4-311.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 26.0 | 142.6 | (100.4-196.5) |  | Male | 175 | 186.8 | 93.7 | (80.3-108.6) |
| Female | 25 | 22.9 | 109.2 | (70.6-161.2) |  | Female | 162 | 162.9 | 99.5 | (84.7-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

25

# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 46 | 41.3 | 111.4 | (81.6-148.6) |  | Male | 30 | 27.9 | 107.4 | (72.5-153.4) |
| Female | 17 | 15.3 | 111.0 | (64.6-177.7) |  | Female | 21 | 23.0 | 91.4 | (56.6-139.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 8.8 | 79.3 | (31.8-163.4) |  | Male | 5 | 8.7 | 57.6 | (18.6-134.4) |
| Female | 7 | 7.2 | 97.6 | (39.1-201.0) |  | Female | 6 | 7.0 | 86.1 | (31.4-187.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 16 | 24.9 | 64.1 | (36.6-104.2) |
| Female | 173 | 178.3 | 97.0 | (83.1-112.6) |  | Female | 19 | 21.9 | 86.8 | (52.2-135.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 20.7 | 101.6 | (62.8-155.3) |
| Female | 6 | 6.3 | 95.2 | (34.8-207.3) |  | Female | 12 | 9.4 | 128.3 | (66.2-224.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 56 | 46.3 | 120.9 | (91.3-157.1) |  |  |  |  |  |  |
| Female | 45 | 46.9 | 96.0 | (70.0-128.4) |  | Female | 24 | 15.8 | 151.9 | (97.3-226.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 11.3 | 97.0 | (48.4-173.7) |  | Male | 17 | 14.8 | 114.7 | (66.8-183.7) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 14 | 15.3 | 91.6 | (50.0-153.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 3.6 | 247.7 | (113.0-470.3) |  | Male | 135 | 146.3 | 92.3 | (77.3-109.2) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 24.4 | 65.5 | (37.4-106.4) |  | Male | 5 | 9.9 | 50.4 | (16.2-117.5) |
| Female | 10 | 14.0 | 71.6 | (34.3-131.7) |  | Female | 8 | 6.0 | 133.9 | (57.7-263.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 6.7 | 149.4 | (71.5-274.7) |  | Male | 8 | 6.9 | 115.2 | (49.6-226.9) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 17.4 | 80.5 | (43.9-135.0) |  | Male | 12 | 11.8 | 101.9 | (52.6-178.0) |
| Female | 6 | 12.9 | 46.4 | (16.9-100.9) |  | Female | 21 | 34.7 | 60.4 | (37.4-92.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 15.2 | 92.3 | (50.4-154.9) |  |  |  |  |  |  |
| Female | 10 | 5.0 | 201.2 | (96.3-370.1) |  | Female | 47 | 40.2 | 117.0 | (86.0-155.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 98 | 75.4 | 130.0 | (105.6-158.5) |  | Male | 570 | 567.2 | 100.5 | (92.4-109.1) |
| Female | 80 | 82.0 | 97.5 | (77.3-121.4) |  | Female | 589 | 595.7 | 98.9 | (91.0-107.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

26

# Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 20.5 | 131.9 | (86.9-191.9) |  | Male | 11 | 12.5 | 87.7 | (43.7-157.0) |
| Female | 12 | 7.7 | 155.4 | (80.2-271.5) |  | Female | 8 | 10.1 | 79.1 | (34.1-155.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 6 | 3.4 | 176.9 | (64.6-385.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.2 | 80.3 | (36.6-152.4) |
| Female | 73 | 79.0 | 92.4 | (72.4-116.2) |  | Female | 11 | 10.5 | 105.1 | (52.4-188.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 8.6 | 116.7 | (55.9-214.6) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 21.6 | 87.9 | (52.9-137.3) |  |  |  |  |  |  |
| Female | 18 | 23.5 | 76.5 | (45.3-120.9) |  | Female | 11 | 7.1 | 155.5 | (77.5-278.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.1 | 137.7 | (55.2-283.7) |  | Male | 6 | 7.0 | 85.8 | (31.3-186.7) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 5 | 7.9 | 63.3 | (20.4-147.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 52 | 62.1 | 83.8 | (62.5-109.8) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.3 | 126.3 | (67.2-216.0) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 5 | 6.3 | 79.3 | (25.5-185.0) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 2.9 | 237.9 | (95.3-490.1) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.8 | 102.5 | (44.1-202.0) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 6 | 6.1 | 99.0 | (36.1-215.5) |  | Female | 15 | 13.5 | 110.8 | (62.0-182.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 6.5 | 138.8 | (63.3-263.5) |  |  |  |  |  |  |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 21 | 17.5 | 120.0 | (74.2-183.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 35.7 | 81.3 | (54.4-116.7) |  | Male | 237 | 253.2 | 93.6 | (82.0-106.3) |
| Female | 42 | 39.0 | 107.6 | (77.5-145.4) |  | Female | 269 | 273.8 | 98.3 | (86.9-110.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

27

# Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.2 | 115.2 | (42.1-250.8) |  | Male | 6 | 3.4 | 177.6 | (64.8-386.6) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 3.0 | 233.9 | (93.7-482.0) |
| Female | 25 | 21.9 | 114.3 | (74.0-168.7) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.7 | 87.9 | (28.3-205.2) |  |  |  |  |  |  |
| Female | 5 | 5.9 | 85.2 | (27.4-198.8) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 8 | 18.9 | 42.3 | (18.2-83.3) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.0 | 169.5 | (54.6-395.5) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 5 | 3.8 | 132.6 | (42.7-309.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 9.6 | 145.5 | (79.5-244.1) |  | Male | 78 | 70.3 | 111.0 | (87.7-138.5) |
| Female | 16 | 10.9 | 146.8 | (83.8-238.4) |  | Female | 78 | 74.4 | 104.9 | (82.9-130.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

28

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.5 | 93.5 | (37.5-192.6) |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 4.6 | nc | (nc-nc) |
| Female | 36 | 33.1 | 108.9 | (76.2-150.7) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.4 | 82.8 | (33.2-170.7) |  |  |  |  |  |  |
| Female | 8 | 9.7 | 82.9 | (35.7-163.3) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.0 | 293.1 | (107.0-638.1) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 18 | 25.2 | 71.6 | (42.4-113.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 3 | 6.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 11 | 6.9 | 160.3 | (79.9-286.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 13.9 | 122.5 | (71.3-196.2) |  | Male | 86 | 102.5 | 83.9 | (67.1-103.6) |
| Female | 16 | 16.3 | 98.2 | (56.1-159.5) |  | Female | 113 | 113.9 | 99.2 | (81.7-119.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

29

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 99 | 70.7 | 140.1 | (113.8-170.5) |  | Male | 54 | 42.6 | 126.7 | (95.2-165.4) |
| Female | 25 | 24.5 | 102.2 | (66.2-150.9) |  | Female | 46 | 30.6 | 150.5 | (110.2-200.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 11.4 | 96.2 | (48.0-172.2) |  | Male | 12 | 13.7 | 87.9 | (45.4-153.5) |
| Female | 11 | 9.4 | 117.6 | (58.6-210.4) |  | Female | 17 | 10.9 | 156.5 | (91.1-250.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 40 | 37.7 | 106.2 | (75.9-144.7) |
| Female | 304 | 247.9 | 122.6 | (109.2-137.2) |  | Female | 45 | 32.6 | 138.0 | (100.6-184.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 32 | 29.4 | 109.0 | (74.5-153.9) |
| Female | 9 | 7.3 | 123.0 | (56.1-233.5) |  | Female | 17 | 13.6 | 124.8 | (72.7-199.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 59 | 71.9 | 82.0 | (62.4-105.8) |  |  |  |  |  |  |
| Female | 71 | 70.5 | 100.7 | (78.6-127.0) |  | Female | 24 | 22.2 | 108.1 | (69.3-160.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 22 | 18.0 | 122.3 | (76.6-185.1) |  | Male | 31 | 24.4 | 127.3 | (86.5-180.7) |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 21 | 24.4 | 86.2 | (53.3-131.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 267 | 226.6 | 117.8 | (104.1-132.8) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 40 | 35.0 | 114.3 | (81.6-155.6) |  | Male | 20 | 16.0 | 124.8 | (76.2-192.8) |
| Female | 17 | 20.3 | 83.6 | (48.7-133.9) |  | Female | 9 | 9.1 | 99.2 | (45.3-188.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 10.4 | 77.2 | (33.2-152.2) |  | Male | 9 | 6.1 | 146.8 | (67.0-278.7) |
| Female | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 31 | 26.2 | 118.4 | (80.4-168.1) |  | Male | 14 | 14.2 | 98.4 | (53.7-165.1) |
| Female | 29 | 18.4 | 157.9 | (105.7-226.8) |  | Female | 27 | 38.5 | 70.1 | (46.2-102.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 28 | 22.6 | 123.8 | (82.2-178.9) |  |  |  |  |  |  |
| Female | 7 | 7.6 | 91.9 | (36.8-189.3) |  | Female | 54 | 58.5 | 92.3 | (69.3-120.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 88 | 125.3 | 70.2 | (56.3-86.5) |  | Male | 947 | 877.7 | 107.9 | (101.1-115.0) |
| Female | 124 | 129.9 | 95.4 | (79.4-113.8) |  | Female | 935 | 857.1 | 109.1 | (102.2-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

30

# Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 15 | 23.2 | 64.5 | (36.1-106.4) |  | Female | 0 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.9 | 136.0 | (58.6-268.0) |  |  |  |  |  |  |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 19 | 18.1 | 104.9 | (63.1-163.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 5.1 | 117.3 | (42.8-255.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 9.0 | 122.8 | (61.2-219.8) |  | Male | 67 | 70.3 | 95.3 | (73.9-121.0) |
| Female | 5 | 10.9 | 46.0 | (14.8-107.3) |  | Female | 56 | 79.1 | 70.8 | (53.5-92.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

31

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 8 | 10.8 | 73.9 | (31.8-145.6) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 9.1 | 66.1 | (24.1-143.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 6 | 2.5 | 236.7 | (86.4-515.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 30 | 37.4 | 80.3 | (54.1-114.6) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 28 | 35.4 | 79.2 | (52.6-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

32

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 19.6 | 117.3 | (74.3-176.0) |  | Male | 17 | 11.5 | 148.1 | (86.2-237.1) |
| Female | 5 | 6.1 | 82.1 | (26.5-191.6) |  | Female | 2 | 8.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 10.3 | 125.9 | (67.0-215.3) |
| Female | 61 | 63.3 | 96.3 | (73.7-123.7) |  | Female | 6 | 8.2 | 72.9 | (26.6-158.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.5 | 66.8 | (21.5-155.9) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 5 | 3.4 | 146.8 | (47.3-342.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 20.3 | 98.4 | (60.1-151.9) |  |  |  |  |  |  |
| Female | 15 | 18.6 | 80.8 | (45.2-133.2) |  | Female | 0 | 5.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 7 | 6.5 | 107.1 | (42.9-220.6) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.1 | 130.5 | (56.2-257.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 53 | 51.5 | 102.9 | (77.1-134.6) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.9 | 78.7 | (31.5-162.2) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.4 | 134.8 | (64.5-247.9) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 7 | 4.8 | 146.0 | (58.5-300.8) |  | Female | 10 | 10.9 | 91.7 | (43.9-168.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 10 | 13.8 | 72.4 | (34.7-133.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 32.5 | 77.0 | (49.8-113.7) |  | Male | 217 | 227.3 | 95.4 | (83.2-109.0) |
| Female | 27 | 31.5 | 85.8 | (56.5-124.8) |  | Female | 182 | 217.9 | 83.5 | (71.8-96.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

33

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 15.4 | 65.1 | (31.2-119.7) |  | Male | 9 | 10.3 | 87.1 | (39.8-165.4) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 6 | 7.5 | 80.5 | (29.4-175.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.2 | 188.8 | (68.9-410.9) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 11 | 9.2 | 119.7 | (59.7-214.2) |
| Female | 63 | 59.9 | 105.1 | (80.8-134.5) |  | Female | 14 | 6.7 | 208.6 | (113.9-349.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.9 | 76.1 | (27.8-165.6) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 6 | 3.0 | 201.7 | (73.7-439.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 17.1 | 105.5 | (62.5-166.7) |  |  |  |  |  |  |
| Female | 18 | 13.7 | 131.6 | (77.9-208.0) |  | Female | 5 | 5.2 | 96.9 | (31.2-226.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 4.3 | nc | (nc-nc) |  | Male | 3 | 5.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.3 | 139.1 | (50.8-302.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 48 | 58.0 | 82.7 | (61.0-109.7) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.2 | 76.4 | (30.6-157.5) |  | Male | 7 | 3.7 | 188.4 | (75.5-388.1) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.3 | 79.4 | (25.6-185.2) |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 9 | 12.2 | 73.9 | (33.7-140.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 20 | 14.0 | 143.1 | (87.4-221.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 28.7 | 52.3 | (29.3-86.3) |  | Male | 169 | 214.5 | 78.8 | (67.4-91.6) |
| Female | 20 | 24.1 | 83.0 | (50.7-128.2) |  | Female | 202 | 189.0 | 106.9 | (92.7-122.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

34

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 15.2 | 78.9 | (40.7-137.9) |  | Male | 9 | 10.4 | 86.9 | (39.6-165.0) |
| Female | 3 | 5.6 | nc | (nc-nc) |  | Female | 10 | 8.8 | 113.7 | (54.4-209.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.2 | 185.1 | (67.6-402.9) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 17 | 9.3 | 183.0 | (106.5-293.0) |
| Female | 72 | 69.7 | 103.3 | (80.8-130.0) |  | Female | 11 | 8.2 | 134.8 | (67.2-241.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.9 | 76.0 | (27.8-165.5) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 17.2 | 92.9 | (53.1-150.9) |  |  |  |  |  |  |
| Female | 17 | 16.7 | 102.0 | (59.4-163.3) |  | Female | 2 | 6.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.3 | 187.4 | (80.7-369.3) |  | Male | 6 | 5.5 | 108.7 | (39.7-236.5) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.6 | 125.9 | (50.5-259.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 72 | 55.6 | 129.4 | (101.3-163.0) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.1 | 87.5 | (37.7-172.5) |  | Male | 5 | 3.7 | 135.5 | (43.7-316.1) |
| Female | 5 | 5.4 | 92.9 | (29.9-216.8) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.4 | 94.0 | (34.3-204.5) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 5 | 4.8 | 104.0 | (33.5-242.8) |  | Female | 14 | 13.7 | 101.9 | (55.7-170.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.8 | 86.8 | (28.0-202.6) |  |  |  |  |  |  |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 17 | 16.1 | 105.7 | (61.6-169.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 27.8 | 108.1 | (72.9-154.3) |  | Male | 233 | 211.9 | 110.0 | (96.3-125.0) |
| Female | 21 | 31.1 | 67.5 | (41.8-103.2) |  | Female | 212 | 227.0 | 93.4 | (81.2-106.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

35

# Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 26.9 | 96.6 | (63.1-141.6) |  | Male | 16 | 16.9 | 94.6 | (54.1-153.7) |
| Female | 5 | 9.9 | 50.4 | (16.3-117.7) |  | Female | 8 | 14.1 | 56.7 | (24.4-111.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.1 | 137.8 | (55.2-284.0) |  | Male | 6 | 5.3 | 113.7 | (41.5-247.6) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 5 | 4.4 | 112.6 | (36.3-262.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 16 | 15.2 | 105.3 | (60.1-171.0) |
| Female | 130 | 109.9 | 118.3 | (98.8-140.5) |  | Female | 10 | 13.9 | 72.2 | (34.5-132.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 11.8 | 42.5 | (13.7-99.1) |
| Female | 1 | 3.9 | nc | (nc-nc) |  | Female | 6 | 5.8 | 103.5 | (37.8-225.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 28.8 | 73.0 | (45.2-111.6) |  |  |  |  |  |  |
| Female | 25 | 30.3 | 82.5 | (53.4-121.8) |  | Female | 10 | 9.6 | 103.7 | (49.7-190.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.8 | 73.1 | (23.6-170.6) |  | Male | 10 | 9.3 | 107.3 | (51.3-197.3) |
| Female | 4 | 1.9 | nc | (nc-nc) |  | Female | 8 | 10.0 | 80.1 | (34.5-157.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 84 | 85.2 | 98.6 | (78.6-122.0) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 14.2 | 91.5 | (48.7-156.5) |  | Male | 4 | 6.2 | nc | (nc-nc) |
| Female | 5 | 8.7 | 57.5 | (18.5-134.2) |  | Female | 5 | 3.9 | 128.2 | (41.3-299.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 10.8 | nc | (nc-nc) |  | Male | 7 | 6.3 | 110.4 | (44.2-227.4) |
| Female | 5 | 8.2 | 61.1 | (19.7-142.6) |  | Female | 26 | 20.7 | 125.5 | (81.9-183.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 8.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 28 | 24.3 | 115.1 | (76.5-166.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 47.1 | 68.0 | (46.5-95.9) |  | Male | 293 | 342.3 | 85.6 | (76.1-96.0) |
| Female | 41 | 51.6 | 79.5 | (57.0-107.8) |  | Female | 354 | 371.7 | 95.2 | (85.6-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

36

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 5 | 4.3 | 117.5 | (37.9-274.2) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 2.9 | 172.0 | (55.4-401.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 30 | 23.7 | 126.5 | (85.4-180.7) |  | Female | 6 | 2.5 | 242.1 | (88.4-526.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.0 | 128.2 | (58.5-243.4) |  |  |  |  |  |  |
| Female | 6 | 5.0 | 120.2 | (43.9-261.6) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 22.5 | 84.3 | (50.7-131.6) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 5 | 1.8 | 284.0 | (91.5-662.8) |
| Female | 4 | 1.5 | nc | (nc-nc) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 7 | 5.3 | 133.1 | (53.3-274.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 11.7 | 94.1 | (46.9-168.4) |  | Male | 80 | 86.8 | 92.2 | (73.1-114.7) |
| Female | 10 | 9.1 | 110.0 | (52.6-202.3) |  | Female | 90 | 72.6 | 124.1 | (99.7-152.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

37

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.1 | 122.0 | (39.3-284.7) |  | Male | 7 | 2.6 | 271.8 | (108.9-560.0) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 14 | 13.7 | 101.8 | (55.6-170.9) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 12 | 13.5 | 88.6 | (45.7-154.8) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 7.3 | 136.4 | (65.3-250.8) |  | Male | 58 | 52.6 | 110.2 | (83.7-142.5) |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 40 | 44.9 | 89.0 | (63.6-121.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

38

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 1.4 | 346.9 | (111.8-809.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 2.0 | 256.0 | (82.5-597.5) |
| Female | 12 | 12.0 | 100.3 | (51.7-175.1) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 16 | 11.6 | 137.8 | (78.7-223.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 42 | 45.1 | 93.2 | (67.1-125.9) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 39 | 40.3 | 96.7 | (68.8-132.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

39

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 51 | 42.7 | 119.6 | (89.0-157.2) |  | Male | 37 | 27.2 | 136.2 | (95.9-187.7) |
| Female | 21 | 15.9 | 132.1 | (81.8-202.0) |  | Female | 33 | 22.6 | 146.0 | (100.5-205.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 8.1 | 147.5 | (76.1-257.7) |  | Male | 12 | 8.5 | 141.0 | (72.8-246.4) |
| Female | 6 | 7.0 | 85.7 | (31.3-186.5) |  | Female | 5 | 7.1 | 70.2 | (22.6-163.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 25 | 24.3 | 102.9 | (66.5-151.8) |
| Female | 176 | 172.3 | 102.2 | (87.6-118.4) |  | Female | 20 | 22.2 | 90.1 | (55.0-139.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 25 | 19.4 | 128.9 | (83.4-190.2) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 14 | 9.3 | 149.7 | (81.8-251.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 45.7 | 69.9 | (47.8-98.8) |  |  |  |  |  |  |
| Female | 48 | 48.3 | 99.4 | (73.3-131.8) |  | Female | 16 | 15.6 | 102.8 | (58.7-167.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 11.2 | 116.5 | (62.0-199.2) |  | Male | 15 | 15.0 | 100.2 | (56.0-165.3) |
| Female | 5 | 3.1 | 161.5 | (52.0-376.9) |  | Female | 17 | 16.2 | 104.8 | (61.0-167.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 161 | 139.9 | 115.1 | (98.0-134.3) |
| Female | 0 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 22.8 | 96.5 | (60.5-146.2) |  | Male | 3 | 9.9 | nc | (nc-nc) |
| Female | 18 | 13.6 | 132.3 | (78.4-209.2) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.4 | 93.7 | (34.2-203.9) |  | Male | 10 | 5.8 | 171.7 | (82.2-315.8) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 17.1 | 134.4 | (85.2-201.7) |  | Male | 13 | 10.4 | 125.3 | (66.6-214.2) |
| Female | 14 | 13.0 | 107.5 | (58.7-180.3) |  | Female | 35 | 32.6 | 107.2 | (74.7-149.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 14.5 | 103.2 | (57.7-170.2) |  |  |  |  |  |  |
| Female | 12 | 5.0 | 239.6 | (123.7-418.6) |  | Female | 34 | 39.2 | 86.7 | (60.1-121.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 84 | 75.5 | 111.3 | (88.8-137.8) |  | Male | 615 | 553.0 | 111.2 | (102.6-120.4) |
| Female | 95 | 81.5 | 116.6 | (94.3-142.5) |  | Female | 648 | 590.2 | 109.8 | (101.5-118.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

40

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 38.5 | 135.1 | (100.9-177.1) |  | Male | 30 | 26.2 | 114.4 | (77.2-163.3) |
| Female | 17 | 13.5 | 125.7 | (73.2-201.3) |  | Female | 22 | 21.0 | 104.9 | (65.7-158.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 8.3 | 108.1 | (49.3-205.2) |  | Male | 11 | 8.2 | 134.2 | (66.9-240.1) |
| Female | 4 | 6.6 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 23 | 23.6 | 97.5 | (61.8-146.3) |
| Female | 158 | 164.9 | 95.8 | (81.4-112.0) |  | Female | 19 | 19.7 | 96.5 | (58.1-150.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 20.0 | 64.9 | (34.5-111.1) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 9 | 8.4 | 107.1 | (48.9-203.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 43.9 | 75.2 | (51.7-105.6) |  |  |  |  |  |  |
| Female | 54 | 41.5 | 130.2 | (97.8-169.9) |  | Female | 15 | 14.4 | 104.2 | (58.3-171.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 10.9 | 82.6 | (37.7-156.7) |  | Male | 14 | 14.0 | 100.0 | (54.6-167.7) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 10 | 13.5 | 74.0 | (35.4-136.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 140 | 143.4 | 97.7 | (82.2-115.2) |
| Female | 1 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 32 | 23.4 | 136.8 | (93.6-193.2) |  | Male | 10 | 9.3 | 107.5 | (51.4-197.6) |
| Female | 9 | 12.7 | 70.6 | (32.2-134.0) |  | Female | 8 | 5.3 | 151.6 | (65.3-298.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.3 | nc | (nc-nc) |  | Male | 4 | 6.5 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 16.2 | 166.2 | (109.5-241.8) |  | Male | 14 | 11.3 | 123.6 | (67.5-207.3) |
| Female | 19 | 11.5 | 165.0 | (99.3-257.6) |  | Female | 29 | 32.5 | 89.3 | (59.8-128.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 14.5 | 69.0 | (33.0-126.9) |  |  |  |  |  |  |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 29 | 37.2 | 78.0 | (52.2-112.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 74 | 69.9 | 105.8 | (83.1-132.9) |  | Male | 562 | 539.6 | 104.1 | (95.7-113.1) |
| Female | 104 | 73.5 | 141.5 | (115.6-171.4) |  | Female | 559 | 541.3 | 103.3 | (94.9-112.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

41

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 7.0 | 171.3 | (88.4-299.2) |  | Male | 6 | 5.0 | 119.6 | (43.7-260.3) |
| Female | 5 | 3.1 | 160.6 | (51.7-374.7) |  | Female | 5 | 4.9 | 102.0 | (32.9-238.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.2 | nc | (nc-nc) |  | Male | 5 | 4.5 | 111.1 | (35.8-259.2) |
| Female | 31 | 39.0 | 79.5 | (54.0-112.8) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.3 | 84.7 | (33.9-174.6) |  |  |  |  |  |  |
| Female | 5 | 9.7 | 51.5 | (16.6-120.1) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 2.0 | 391.1 | (168.4-770.6) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 27 | 26.6 | 101.6 | (66.9-147.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 3 | 7.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 10 | 8.7 | 114.5 | (54.8-210.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 13.2 | 152.0 | (92.8-234.7) |  | Male | 125 | 101.9 | 122.6 | (102.1-146.1) |
| Female | 13 | 16.2 | 80.1 | (42.6-136.9) |  | Female | 117 | 125.8 | 93.0 | (76.9-111.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

42

# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 4.9 | 143.9 | (57.7-296.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 19 | 17.1 | 111.3 | (67.0-173.8) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 17 | 15.8 | 107.8 | (62.8-172.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

43

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 22 | 19.5 | 113.0 | (70.8-171.2) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 5.4 | 129.7 | (52.0-267.3) |  |  |  |  |  |  |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 24 | 17.8 | 134.9 | (86.4-200.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 10 | 4.4 | 225.3 | (107.9-414.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 8.5 | nc | (nc-nc) |  | Male | 63 | 65.9 | 95.6 | (73.5-122.3) |
| Female | 5 | 7.0 | 71.2 | (22.9-166.0) |  | Female | 48 | 58.2 | 82.5 | (60.9-109.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

44

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 344 | 466.1 | 73.8 | (66.2-82.0) |  | Male | 253 | 319.6 | 79.2 | (69.7-89.6) |
| Female | 140 | 179.4 | 78.1 | (65.7-92.1) |  | Female | 203 | 294.0 | 69.1 | (59.9-79.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 72 | 107.4 | 67.0 | (52.4-84.4) |  | Male | 114 | 95.7 | 119.2 | (98.3-143.2) |
| Female | 71 | 91.8 | 77.3 | (60.4-97.5) |  | Female | 127 | 81.4 | 156.1 | (130.1-185.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 15 | 16.0 | 93.7 | (52.4-154.5) |  | Male | 284 | 287.5 | 98.8 | (87.6-111.0) |
| Female | 1903 | 2058.3 | 92.5 | (88.3-96.7) |  | Female | 256 | 262.0 | 97.7 | (86.1-110.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 262 | 225.7 | 116.1 | (102.4-131.0) |
| Female | 96 | 81.4 | 117.9 | (95.5-144.0) |  | Female | 114 | 109.2 | 104.4 | (86.1-125.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 561 | 515.8 | 108.8 | (100.0-118.2) |  |  |  |  |  |  |
| Female | 577 | 549.2 | 105.1 | (96.7-114.0) |  | Female | 188 | 187.1 | 100.5 | (86.6-115.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 118 | 124.3 | 95.0 | (78.6-113.7) |  | Male | 157 | 164.7 | 95.3 | (81.0-111.5) |
| Female | 36 | 34.9 | 103.2 | (72.3-142.9) |  | Female | 179 | 179.6 | 99.7 | (85.6-115.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 61 | 56.6 | 107.7 | (82.4-138.4) |  | Male | 1865 | 1570.7 | 118.7 | (113.4-124.2) |
| Female | 48 | 51.2 | 93.8 | (69.2-124.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 229 | 268.2 | 85.4 | (74.7-97.2) |  | Male | 164 | 110.9 | 147.9 | (126.1-172.3) |
| Female | 172 | 163.8 | 105.0 | (89.9-121.9) |  | Female | 104 | 70.7 | 147.0 | (120.1-178.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 90 | 72.5 | 124.2 | (99.9-152.7) |  | Male | 98 | 118.9 | 82.5 | (66.9-100.5) |
| Female | 17 | 23.7 | 71.7 | (41.7-114.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 156 | 204.6 | 76.2 | (64.7-89.2) |  | Male | 153 | 141.3 | 108.3 | (91.8-126.9) |
| Female | 129 | 160.0 | 80.6 | (67.3-95.8) |  | Female | 473 | 475.3 | 99.5 | (90.7-108.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 273 | 164.1 | 166.4 | (147.2-187.3) |  |  |  |  |  |  |
| Female | 91 | 58.0 | 156.8 | (126.2-192.5) |  | Female | 438 | 460.0 | 95.2 | (86.5-104.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 911 | 831.9 | 109.5 | (102.5-116.9) |  | Male | 6682 | 6365.2 | 105.0 | (102.5-107.5) |
| Female | 850 | 948.4 | 89.6 | (83.7-95.9) |  | Female | 6758 | 7078.4 | 95.5 | (93.2-97.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

45

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 28.1 | 117.4 | (80.8-164.9) |  | Male | 23 | 17.0 | 135.2 | (85.7-202.9) |
| Female | 10 | 10.2 | 98.2 | (47.0-180.5) |  | Female | 14 | 12.5 | 112.1 | (61.2-188.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.7 | 128.6 | (47.0-280.0) |  | Male | 8 | 5.5 | 145.1 | (62.5-285.9) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 11 | 15.1 | 72.7 | (36.2-130.0) |
| Female | 83 | 98.3 | 84.4 | (67.2-104.6) |  | Female | 9 | 13.4 | 67.2 | (30.7-127.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 11.5 | 147.5 | (85.9-236.2) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 5 | 5.5 | 90.6 | (29.2-211.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 28.6 | 73.4 | (45.4-112.1) |  |  |  |  |  |  |
| Female | 27 | 30.0 | 90.0 | (59.3-130.9) |  | Female | 12 | 8.9 | 134.7 | (69.5-235.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 7.1 | 169.7 | (87.6-296.5) |  | Male | 9 | 9.5 | 94.4 | (43.1-179.1) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 10 | 10.3 | 97.4 | (46.6-179.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 90 | 86.3 | 104.3 | (83.9-128.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 13.8 | 65.1 | (29.7-123.6) |  | Male | 6 | 6.4 | 94.2 | (34.4-205.0) |
| Female | 7 | 8.2 | 85.9 | (34.4-176.9) |  | Female | 5 | 3.9 | 128.1 | (41.3-299.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 4.1 | 244.6 | (117.1-449.8) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 10.5 | 66.4 | (26.6-136.7) |  | Male | 2 | 5.8 | nc | (nc-nc) |
| Female | 5 | 7.8 | 64.3 | (20.7-149.9) |  | Female | 19 | 15.7 | 120.8 | (72.7-188.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.0 | 77.6 | (31.1-159.9) |  |  |  |  |  |  |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 18 | 22.4 | 80.4 | (47.6-127.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 55 | 49.5 | 111.2 | (83.7-144.7) |  | Male | 358 | 346.2 | 103.4 | (93.0-114.7) |
| Female | 62 | 52.1 | 119.1 | (91.3-152.7) |  | Female | 324 | 347.7 | 93.2 | (83.3-103.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

46

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 26 | 20.1 | 129.1 | (84.3-189.1) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.6 | 88.9 | (28.6-207.4) |  |  |  |  |  |  |
| Female | 5 | 4.2 | 118.7 | (38.2-276.9) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 19 | 20.3 | 93.8 | (56.4-146.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.5 | (35.0-253.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 9.1 | 65.7 | (24.0-143.1) |  | Male | 61 | 71.8 | 85.0 | (65.0-109.2) |
| Female | 9 | 7.3 | 123.3 | (56.3-234.1) |  | Female | 70 | 60.9 | 115.0 | (89.7-145.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

47

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 10.1 | 59.1 | (21.6-128.7) |  | Male | 18 | 6.6 | 273.6 | (162.0-432.4) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 9 | 4.4 | 205.2 | (93.6-389.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 41 | 36.4 | 112.6 | (80.8-152.8) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 11.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 8.7 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 46 | 36.7 | 125.3 | (91.7-167.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.0 | 126.3 | (40.7-294.7) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 5 | 2.4 | 208.2 | (67.1-485.9) |  | Female | 11 | 6.6 | 166.4 | (83.0-297.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 8.6 | 58.2 | (18.8-135.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 18.5 | 48.5 | (22.1-92.1) |  | Male | 116 | 136.7 | 84.9 | (70.1-101.8) |
| Female | 9 | 15.9 | 56.5 | (25.8-107.3) |  | Female | 115 | 116.8 | 98.5 | (81.3-118.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

48

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.0 | 99.3 | (32.0-231.8) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 8 | 2.3 | 348.3 | (150.0-686.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 4 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 27 | 18.7 | 144.5 | (95.2-210.3) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 4.7 | 171.1 | (73.7-337.2) |  | Female | 4 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 11 | 17.2 | 63.8 | (31.8-114.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 9.0 | nc | (nc-nc) |  | Male | 53 | 67.1 | 79.0 | (59.1-103.3) |
| Female | 5 | 8.0 | 62.5 | (20.2-146.0) |  | Female | 72 | 60.2 | 119.6 | (93.6-150.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

49

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 40.0 | 129.8 | (97.0-170.3) |  | Male | 33 | 25.2 | 130.9 | (90.1-183.9) |
| Female | 24 | 16.5 | 145.5 | (93.2-216.5) |  | Female | 23 | 21.7 | 105.9 | (67.1-158.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.4 | 94.0 | (37.7-193.8) |  | Male | 7 | 7.9 | 89.0 | (35.6-183.3) |
| Female | 5 | 6.7 | 75.1 | (24.2-175.3) |  | Female | 7 | 7.2 | 97.1 | (38.9-200.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 25 | 22.5 | 111.0 | (71.8-163.8) |
| Female | 183 | 165.0 | 110.9 | (95.4-128.2) |  | Female | 21 | 22.1 | 95.0 | (58.8-145.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 17.6 | 119.5 | (73.9-182.7) |
| Female | 10 | 5.5 | 180.7 | (86.5-332.3) |  | Female | 10 | 9.1 | 109.7 | (52.5-201.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 54 | 42.5 | 127.1 | (95.5-165.8) |  |  |  |  |  |  |
| Female | 67 | 50.1 | 133.7 | (103.6-169.8) |  | Female | 13 | 14.9 | 87.0 | (46.3-148.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 10.2 | 146.9 | (82.1-242.3) |  | Male | 14 | 13.9 | 101.0 | (55.2-169.4) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 18 | 16.7 | 107.8 | (63.9-170.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 122 | 125.1 | 97.5 | (81.0-116.4) |
| Female | 4 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 20.8 | 91.5 | (55.1-142.9) |  | Male | 10 | 9.3 | 107.8 | (51.6-198.3) |
| Female | 15 | 13.4 | 111.7 | (62.5-184.2) |  | Female | 7 | 6.5 | 107.3 | (43.0-221.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 5 | 5.1 | 98.0 | (31.6-228.6) |
| Female | 6 | 1.9 | 308.1 | (112.5-670.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 15.9 | 62.7 | (30.0-115.4) |  | Male | 8 | 9.3 | 85.9 | (37.0-169.3) |
| Female | 21 | 13.1 | 159.9 | (99.0-244.5) |  | Female | 36 | 29.7 | 121.3 | (84.9-167.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 13.2 | 136.2 | (80.7-215.3) |  |  |  |  |  |  |
| Female | 5 | 5.0 | 100.7 | (32.5-235.0) |  | Female | 36 | 36.4 | 98.9 | (69.3-137.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 61 | 70.0 | 87.1 | (66.6-111.9) |  | Male | 528 | 507.5 | 104.0 | (95.4-113.3) |
| Female | 88 | 82.5 | 106.7 | (85.6-131.5) |  | Female | 648 | 579.4 | 111.8 | (103.4-120.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

50

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 17.8 | 101.2 | (59.9-159.9) |  | Male | 15 | 10.3 | 145.1 | (81.2-239.4) |
| Female | 8 | 6.5 | 123.8 | (53.3-243.9) |  | Female | 13 | 7.5 | 173.6 | (92.3-296.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 14 | 9.0 | 154.8 | (84.5-259.7) |
| Female | 84 | 60.7 | 138.4 | (110.4-171.3) |  | Female | 13 | 8.4 | 155.2 | (82.5-265.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.7 | 105.0 | (42.1-216.3) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 17.4 | 69.0 | (35.6-120.5) |  |  |  |  |  |  |
| Female | 16 | 18.6 | 86.0 | (49.1-139.7) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 6 | 5.9 | 101.5 | (37.1-221.0) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 3 | 6.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 70 | 53.2 | 131.7 | (102.7-166.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 8.2 | 73.1 | (26.7-159.1) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 5 | 5.1 | 98.3 | (31.7-229.3) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.2 | 112.2 | (45.0-231.2) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 6 | 4.7 | 126.8 | (46.3-276.1) |  | Female | 7 | 8.7 | 80.8 | (32.4-166.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 11 | 14.2 | 77.3 | (38.6-138.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 31.8 | 87.9 | (58.4-127.1) |  | Male | 213 | 211.4 | 100.7 | (87.7-115.2) |
| Female | 18 | 33.7 | 53.4 | (31.7-84.5) |  | Female | 215 | 215.8 | 99.6 | (86.8-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

51

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 23.7 | 80.1 | (48.2-125.2) |  | Male | 15 | 16.3 | 91.9 | (51.4-151.6) |
| Female | 13 | 7.3 | 177.4 | (94.4-303.4) |  | Female | 17 | 11.7 | 145.5 | (84.7-233.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.3 | 112.7 | (41.2-245.4) |  | Male | 2 | 5.0 | nc | (nc-nc) |
| Female | 6 | 3.7 | 161.3 | (58.9-351.0) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 10 | 14.8 | 67.5 | (32.3-124.1) |
| Female | 92 | 88.5 | 104.0 | (83.8-127.5) |  | Female | 12 | 10.8 | 111.5 | (57.5-194.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 12.4 | 113.0 | (61.7-189.6) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.7 | (35.0-253.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 27.1 | 84.8 | (53.8-127.3) |  |  |  |  |  |  |
| Female | 25 | 22.4 | 111.4 | (72.1-164.4) |  | Female | 11 | 7.9 | 139.3 | (69.4-249.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.6 | 91.2 | (33.3-198.6) |  | Male | 13 | 8.6 | 151.0 | (80.3-258.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 10 | 7.3 | 137.2 | (65.7-252.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 81 | 84.4 | 96.0 | (76.3-119.3) |
| Female | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 14.4 | 55.6 | (24.0-109.6) |  | Male | 5 | 5.8 | 86.4 | (27.8-201.6) |
| Female | 7 | 6.8 | 102.5 | (41.1-211.3) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 10.3 | 48.3 | (15.6-112.8) |  | Male | 11 | 7.2 | 152.4 | (76.0-272.7) |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 26 | 18.4 | 141.4 | (92.3-207.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 8.8 | 158.6 | (86.6-266.1) |  |  |  |  |  |  |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 15 | 20.1 | 74.5 | (41.7-122.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 42.4 | 120.2 | (89.5-158.1) |  | Male | 314 | 330.5 | 95.0 | (84.8-106.1) |
| Female | 29 | 39.1 | 74.1 | (49.6-106.5) |  | Female | 304 | 293.9 | 103.4 | (92.1-115.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

52

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 16 | 18.5 | 86.6 | (49.5-140.7) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.5 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 10 | 14.1 | 70.7 | (33.9-130.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 2.2 | 225.8 | (72.8-526.9) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 6.3 | 126.5 | (54.5-249.3) |  | Male | 50 | 50.0 | 100.1 | (74.3-132.0) |
| Female | 9 | 8.7 | 103.5 | (47.2-196.5) |  | Female | 45 | 60.0 | 75.0 | (54.7-100.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

53

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 81 | 82.4 | 98.3 | (78.1-122.2) |  | Male | 27 | 54.4 | 49.7 | (32.7-72.2) |
| Female | 34 | 31.4 | 108.3 | (75.0-151.3) |  | Female | 25 | 47.0 | 53.2 | (34.4-78.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 17 | 17.6 | 96.4 | (56.1-154.4) |  | Male | 10 | 16.9 | 59.3 | (28.4-109.0) |
| Female | 18 | 15.0 | 119.8 | (71.0-189.3) |  | Female | 13 | 14.2 | 91.6 | (48.7-156.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 47 | 49.1 | 95.7 | (70.3-127.3) |
| Female | 302 | 357.4 | 84.5 | (75.2-94.6) |  | Female | 37 | 44.8 | 82.6 | (58.2-113.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 41 | 39.5 | 103.7 | (74.4-140.7) |
| Female | 26 | 12.9 | 200.9 | (131.2-294.4) |  | Female | 20 | 18.9 | 105.9 | (64.6-163.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 114 | 91.1 | 125.1 | (103.2-150.3) |  |  |  |  |  |  |
| Female | 108 | 96.5 | 111.9 | (91.8-135.1) |  | Female | 42 | 31.8 | 132.0 | (95.1-178.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 22.0 | 91.0 | (55.6-140.6) |  | Male | 31 | 29.2 | 106.2 | (72.2-150.8) |
| Female | 8 | 6.1 | 131.2 | (56.5-258.5) |  | Female | 43 | 31.6 | 136.3 | (98.6-183.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 7.3 | 68.1 | (21.9-158.9) |  | Male | 286 | 278.3 | 102.8 | (91.2-115.4) |
| Female | 5 | 6.3 | 79.3 | (25.5-184.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 57 | 46.6 | 122.2 | (92.6-158.4) |  | Male | 25 | 19.6 | 127.7 | (82.6-188.5) |
| Female | 27 | 28.3 | 95.4 | (62.9-138.8) |  | Female | 13 | 12.4 | 105.1 | (55.9-179.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 12.8 | 148.0 | (89.1-231.1) |  | Male | 13 | 13.7 | 94.9 | (50.5-162.2) |
| Female | 4 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 35.0 | 77.0 | (50.8-112.1) |  | Male | 32 | 22.2 | 144.1 | (98.5-203.4) |
| Female | 21 | 27.1 | 77.5 | (47.9-118.4) |  | Female | 90 | 71.4 | 126.0 | (101.3-154.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 40 | 29.2 | 136.9 | (97.8-186.4) |  |  |  |  |  |  |
| Female | 16 | 10.1 | 159.2 | (90.9-258.5) |  | Female | 79 | 79.7 | 99.2 | (78.5-123.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 186 | 146.9 | 126.6 | (109.1-146.2) |  | Male | 1171 | 1104.2 | 106.0 | (100.1-112.3) |
| Female | 206 | 165.7 | 124.3 | (107.9-142.5) |  | Female | 1254 | 1209.5 | 103.7 | (98.0-109.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

54

# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.1 | 121.5 | (39.2-283.6) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 13 | 15.5 | 83.9 | (44.6-143.5) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 4.3 | 140.2 | (51.2-305.1) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 13 | 16.1 | 80.9 | (43.0-138.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 0.5 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 7.6 | 91.5 | (36.7-188.6) |  | Male | 41 | 57.2 | 71.7 | (51.5-97.3) |
| Female | 13 | 7.6 | 170.1 | (90.5-290.9) |  | Female | 61 | 52.9 | 115.2 | (88.1-148.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

55

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 51 | 53.0 | 96.3 | (71.7-126.6) |  | Male | 46 | 34.4 | 133.8 | (98.0-178.5) |
| Female | 14 | 22.7 | 61.6 | (33.6-103.3) |  | Female | 34 | 33.4 | 101.7 | (70.4-142.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 10.5 | 114.2 | (58.9-199.5) |  | Male | 13 | 10.7 | 121.7 | (64.7-208.0) |
| Female | 12 | 10.4 | 115.5 | (59.6-201.8) |  | Female | 8 | 10.2 | 78.5 | (33.8-154.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 39 | 30.5 | 127.8 | (90.9-174.7) |
| Female | 238 | 242.5 | 98.2 | (86.1-111.5) |  | Female | 38 | 31.9 | 119.2 | (84.4-163.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 24.0 | 87.5 | (54.2-133.8) |
| Female | 1 | 8.8 | nc | (nc-nc) |  | Female | 7 | 13.2 | 53.0 | (21.2-109.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 55.9 | 68.0 | (48.1-93.3) |  |  |  |  |  |  |
| Female | 41 | 67.8 | 60.5 | (43.4-82.0) |  | Female | 33 | 22.1 | 149.0 | (102.6-209.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 14.0 | 35.6 | (11.5-83.2) |  | Male | 17 | 18.5 | 91.9 | (53.5-147.1) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 25 | 23.0 | 108.7 | (70.4-160.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 175 | 180.8 | 96.8 | (83.0-112.3) |
| Female | 7 | 5.0 | 140.1 | (56.1-288.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 29.0 | 106.8 | (72.6-151.7) |  | Male | 8 | 12.3 | 64.8 | (27.9-127.8) |
| Female | 17 | 19.7 | 86.4 | (50.3-138.4) |  | Female | 9 | 8.8 | 102.4 | (46.7-194.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 8.2 | nc | (nc-nc) |  | Male | 14 | 9.0 | 156.3 | (85.4-262.2) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 21.3 | 140.5 | (94.8-200.6) |  | Male | 16 | 13.6 | 117.5 | (67.1-190.9) |
| Female | 26 | 19.1 | 136.4 | (89.1-199.9) |  | Female | 50 | 49.6 | 100.8 | (74.8-132.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 17.9 | 39.1 | (15.7-80.6) |  |  |  |  |  |  |
| Female | 5 | 7.2 | 69.8 | (22.5-162.9) |  | Female | 42 | 55.7 | 75.4 | (54.4-102.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 62 | 95.4 | 65.0 | (49.8-83.3) |  | Male | 640 | 699.4 | 91.5 | (84.6-98.9) |
| Female | 80 | 118.6 | 67.5 | (53.5-84.0) |  | Female | 764 | 845.6 | 90.4 | (84.1-97.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

56

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 11 | 11.9 | 92.8 | (46.3-166.0) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 8.7 | 114.6 | (54.9-210.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.6 | nc | (nc-nc) |  | Male | 30 | 34.0 | 88.2 | (59.5-125.9) |
| Female | 5 | 6.2 | 80.5 | (25.9-187.8) |  | Female | 36 | 41.0 | 87.8 | (61.5-121.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

57

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 30.7 | 87.8 | (57.9-127.8) |  | Male | 18 | 19.2 | 93.6 | (55.4-147.9) |
| Female | 5 | 10.8 | 46.3 | (14.9-108.2) |  | Female | 15 | 14.5 | 103.1 | (57.7-170.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 5.5 | 162.8 | (74.3-309.2) |  | Male | 7 | 6.1 | 115.7 | (46.3-238.3) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 21 | 17.0 | 123.7 | (76.6-189.1) |
| Female | 127 | 115.4 | 110.0 | (91.7-130.9) |  | Female | 14 | 14.7 | 95.0 | (51.9-159.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 13.1 | 91.9 | (47.4-160.5) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.8 | (26.0-188.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 32.0 | 96.9 | (65.8-137.5) |  |  |  |  |  |  |
| Female | 27 | 31.7 | 85.3 | (56.2-124.1) |  | Female | 7 | 10.2 | 68.4 | (27.4-141.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 7.8 | nc | (nc-nc) |  | Male | 12 | 10.5 | 113.8 | (58.7-198.8) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.6 | 94.5 | (45.2-173.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 97 | 94.8 | 102.3 | (83.0-124.8) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 15.6 | 128.0 | (78.2-197.7) |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 5 | 9.3 | 53.5 | (17.2-124.9) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 11.9 | 142.6 | (83.0-228.3) |  | Male | 12 | 6.9 | 172.9 | (89.2-302.0) |
| Female | 7 | 8.5 | 82.7 | (33.1-170.4) |  | Female | 28 | 20.7 | 135.5 | (90.0-195.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 10.0 | 100.1 | (47.9-184.1) |  |  |  |  |  |  |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 31 | 25.9 | 119.6 | (81.3-169.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 54.5 | 73.4 | (52.5-100.0) |  | Male | 394 | 385.3 | 102.2 | (92.4-112.9) |
| Female | 63 | 58.3 | 108.1 | (83.1-138.3) |  | Female | 392 | 394.2 | 99.5 | (89.8-109.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

58

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 46 | 74.4 | 61.8 | (45.3-82.5) |  | Male | 56 | 51.6 | 108.5 | (81.9-140.8) |
| Female | 17 | 30.0 | 56.7 | (33.0-90.9) |  | Female | 44 | 49.7 | 88.5 | (64.3-118.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 20 | 17.6 | 113.8 | (69.5-175.7) |  | Male | 18 | 15.0 | 119.7 | (70.9-189.2) |
| Female | 12 | 15.2 | 78.9 | (40.7-137.8) |  | Female | 7 | 13.6 | 51.5 | (20.6-106.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 42 | 46.1 | 91.2 | (65.7-123.2) |
| Female | 299 | 338.6 | 88.3 | (78.6-98.9) |  | Female | 34 | 43.8 | 77.6 | (53.7-108.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 37 | 35.3 | 104.7 | (73.7-144.4) |
| Female | 9 | 13.7 | 65.5 | (29.9-124.4) |  | Female | 16 | 18.2 | 88.0 | (50.3-142.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 71 | 80.9 | 87.7 | (68.5-110.7) |  |  |  |  |  |  |
| Female | 69 | 90.6 | 76.1 | (59.2-96.3) |  | Female | 21 | 31.2 | 67.3 | (41.7-102.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 19.7 | 71.1 | (38.9-119.4) |  | Male | 32 | 26.1 | 122.5 | (83.8-172.9) |
| Female | 5 | 5.9 | 85.4 | (27.5-199.3) |  | Female | 26 | 30.1 | 86.5 | (56.5-126.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 10.2 | 68.5 | (27.4-141.1) |  | Male | 247 | 250.3 | 98.7 | (86.7-111.8) |
| Female | 3 | 8.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 42.4 | 77.8 | (53.6-109.3) |  | Male | 11 | 17.6 | 62.5 | (31.2-111.9) |
| Female | 14 | 27.1 | 51.6 | (28.2-86.6) |  | Female | 8 | 11.7 | 68.2 | (29.4-134.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 11.4 | nc | (nc-nc) |  | Male | 26 | 22.7 | 114.7 | (74.9-168.1) |
| Female | 1 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 32.8 | 79.2 | (51.7-116.1) |  | Male | 27 | 23.3 | 115.7 | (76.2-168.4) |
| Female | 18 | 26.6 | 67.8 | (40.1-107.1) |  | Female | 78 | 80.6 | 96.8 | (76.5-120.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 25.5 | 70.5 | (41.7-111.4) |  |  |  |  |  |  |
| Female | 13 | 9.7 | 133.8 | (71.2-228.9) |  | Female | 67 | 76.7 | 87.3 | (67.7-110.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 106 | 132.7 | 79.9 | (65.4-96.6) |  | Male | 901 | 1018.5 | 88.5 | (82.8-94.4) |
| Female | 103 | 158.1 | 65.1 | (53.2-79.0) |  | Female | 940 | 1176.9 | 79.9 | (74.8-85.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

59

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 26.0 | 80.6 | (49.9-123.2) |  | Male | 18 | 16.2 | 111.2 | (65.9-175.8) |
| Female | 7 | 9.6 | 72.8 | (29.2-150.1) |  | Female | 16 | 13.0 | 123.0 | (70.3-199.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 9 | 5.2 | 174.5 | (79.6-331.2) |
| Female | 6 | 4.0 | 148.3 | (54.1-322.8) |  | Female | 6 | 4.3 | 139.8 | (51.0-304.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 10 | 14.5 | 69.0 | (33.0-127.0) |
| Female | 100 | 103.0 | 97.1 | (79.0-118.1) |  | Female | 16 | 13.2 | 121.6 | (69.5-197.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.3 | 97.5 | (48.6-174.4) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 9 | 5.5 | 163.1 | (74.4-309.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 27.4 | 102.1 | (67.9-147.6) |  |  |  |  |  |  |
| Female | 30 | 28.8 | 104.2 | (70.3-148.8) |  | Female | 6 | 9.1 | 65.6 | (24.0-142.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.7 | 120.2 | (51.8-236.9) |  | Male | 9 | 9.0 | 100.3 | (45.8-190.4) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 8 | 9.7 | 82.7 | (35.6-163.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 83 | 81.9 | 101.4 | (80.7-125.7) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 13.5 | 66.8 | (30.5-126.7) |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 4 | 8.3 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 10.1 | 167.6 | (97.6-268.3) |  | Male | 10 | 5.9 | 169.5 | (81.2-311.8) |
| Female | 7 | 7.7 | 91.3 | (36.6-188.1) |  | Female | 29 | 18.0 | 160.8 | (107.7-230.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 8.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 30 | 23.3 | 128.8 | (86.9-183.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 45.7 | 100.6 | (73.6-134.1) |  | Male | 327 | 328.5 | 99.5 | (89.0-110.9) |
| Female | 54 | 50.5 | 106.9 | (80.3-139.5) |  | Female | 371 | 351.1 | 105.7 | (95.2-117.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

60